The impact of blood coagulability on atherosclerosis and cardiovascular disease

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 7, 2012, Pages 1207-1216

  Loeffen, R ^a   Spronk, H M H ^a   ten Cate, H ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Atherosclerosis; Atherothrombosis; Coagulation; Hypercoagulability; Thrombin

Indexed keywords

ACTIVATED PROTEIN C; APOLIPOPROTEIN E; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; D DIMER; FIBRINOGEN; HEPARIN COFACTOR II; INTERLEUKIN 6; MESSENGER RNA; PROTEIN C; PROTEINASE ACTIVATED RECEPTOR; PROTHROMBIN; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANGIOGENESIS; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL PROLIFERATION; CHEMOTAXIS; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME DEGRADATION; FOAM CELL; GENETIC DISORDER; HUMAN; HYPERCOAGULABILITY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MACROPHAGE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; REVIEW; SMOOTH MUSCLE FIBER; THROMBOPHILIA;

ANIMALS; ATHEROSCLEROSIS; BLOOD COAGULATION; CARDIOVASCULAR DISEASES; HUMANS; THROMBIN; THROMBOPHILIA;

EID: 84863442507     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04782.x     Document Type: Review

References (132)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
3. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
4. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006; 86: 515-81.
5. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011; 145: 341-55.
6. Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-94.
7. Khrenov AV, Ananyeva NM, Griffin JH, Saenko EL. Coagulation pathways in atherothrombosis. Trends Cardiovasc Med 2002; 12: 317-24.
8. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-43.
9. Wilcox JN, Noguchi S, Casanova J. Extrahepatic synthesis of factor VII in human atherosclerotic vessels. Arterioscler Thromb Vasc Biol 2003; 23: 136-41.
10. Yoshii Y, Okada Y, Sasaki S, Mori H, Oida K, Ishii H. Expression of thrombomodulin in human aortic smooth muscle cells with special reference to atherosclerotic lesion types and age differences. Med Electron Microsc 2003; 36: 165-72.
11. Borissoff JI, Heeneman S, Kilinc E, Kassák P, van Oerle R, Winckers K, Govers-Riemslag JWP, Hamulyak K, Hackeng TM, Daemen MJAP, ten Cate H, Spronk HMH. Early atherosclerosis exhibits an enhanced procoagulant state. Circulation 2010; 122: 821-30.
12. Bini A, Fenoglio JJ, Mesa-Tejada R, Kudryk B, Kaplan KL. Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Use of monoclonal antibodies. Arteriosclerosis 1989; 9: 109-21.
13. Smith EB, Keen GA, Grant A, Stirk C. Fate of fibrinogen in human arterial intima. Arteriosclerosis 1990; 10: 263-75.
14. Bini A, Mesa-Tejada R, Fenoglio JJ, Kudryk B, Kaplan KL. Immunohistochemical characterization of fibrin(ogen)-related antigens in human tissues using monoclonal antibodies. Lab Invest 1989; 60: 814-21.
15. Ikari Y, Yee KO, Hatsukami TS, Schwartz SM. Human carotid artery smooth muscle cells rarely express alpha(v)beta3 integrin at sites of recent plaque rupture. Thromb Haemost 2000; 84: 338-44.
16. Valenzuela R, Shainoff JR, DiBello PM, Urbanic DA, Anderson JM, Matsueda GR, Kudryk BJ. Immunoelectrophoretic and immunohistochemical characterizations of fibrinogen derivatives in atherosclerotic aortic intimas and vascular prosthesis pseudo-intimas. Am J Pathol 1992; 141: 861-80.
17. Naito M, Stirk CM, Smith EB, Thompson WD. Smooth muscle cell outgrowth stimulated by fibrin degradation products. The potential role of fibrin fragment E in restenosis and atherogenesis. Thromb Res 2000; 98: 165-74.
18. Ishida T, Tanaka K. Effects of fibrin and fibrinogen-degradation products on the growth of rabbit aortic smooth muscle cells in culture. Atherosclerosis 1982; 44: 161-74.
19. Ge M, Ryan TJ, Lum H, Malik AB. Fibrinogen degradation product fragment D increases endothelial monolayer permeability. Am J Physiol 1991; 261: L283-9.
20. Richardson DL, Pepper DS, Kay AB. Chemotaxis for human monocytes by fibrinogen-derived peptides. Br J Haematol 1976; 32: 507-13.
21. Robson SC, Shephard EG, Kirsch RE. Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1 beta, IL-6 and plasminogen activator inhibitors from monocytes in vitro. Br J Haematol 1994; 86: 322-6.
22. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 3: 1800-14.
23. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258-64.
24. Borissoff JI, Spronk HMH, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med 2011; 364: 1746-60.
25. Borissoff JI, Spronk HMH, Heeneman S, ten Cate H. Is thrombin a key player in the 'coagulation-atherogenesis' maze? Cardiovasc Res 2009; 82: 392-403.
26. Gailani D, Renné T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vasc Biol 2007; 27: 2507-13.
27. Seehaus S, Shahzad K, Kashif M, Vinnikov IA, Schiller M, Wang H, Madhusudhan T, Eckstein V, Bierhaus A, Bea F, Blessing E, Weiler H, Frommhold D, Nawroth PP, Isermann B. Hypercoagulability inhibits monocyte transendothelial migration through protease-activated receptor-1-, phospholipase-Cbeta-, phosphoinositide 3-kinase-, and nitric oxide-dependent signaling in monocytes and promotes plaque stability. Circulation 2009; 120: 774-84.
28. Castellino FJ, Ganopolsky JG, Noria F, Sandoval-Cooper MJ, Ploplis VA. Focal arterial inflammation is augmented in mice with a deficiency of the protein C gene. Thromb Haemost 2006; 96: 794-801.
29. Westrick RJ, Bodary PF, Xu Z, Shen YC, Broze GJ, Eitzman DT. Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice. Circulation 2001; 103: 3044-6.
30. Vicente CP, He L, Tollefsen DM. Accelerated atherogenesis and neointima formation in heparin cofactor II deficient mice. Blood 2007; 110: 4261-7.
31. Eitzman DT, Westrick RJ, Shen Y, Bodary PF, Gu S, Manning SL, Dobies SL, Ginsburg D. Homozygosity for factor V Leiden leads to enhanced thrombosis and atherosclerosis in mice. Circulation 2005; 111: 1822-5.
32. Breslow JL. Mouse models of atherosclerosis. Science 1996; 272: 685-8.
33. Daugherty A. Mouse models of atherosclerosis. Am J Med Sci 2002; 323: 3-10.
34. Khallou-Laschet J, Caligiuri G, Tupin E, Gaston A-T, Poirier B, Groyer E, Urbain D, Maisnier-Patin S, Sarkar R, Kaveri SV, Lacroix-Desmazes S, Nicoletti A. Role of the intrinsic coagulation pathway in atherogenesis assessed in hemophilic apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2005; 25: e123-6.
35. Fabri DR, de Paula EV, Costa DSP, Annichino-Bizzacchi JM, Arruda VR. Novel insights into the development of atherosclerosis in hemophilia A mouse models. J Thromb Haemost 2011; 9: 1556-61.
36. Xiao Q, Danton MJ, Witte DP, Kowala MC, Valentine MT, Degen JL. Fibrinogen deficiency is compatible with the development of atherosclerosis in mice. J Clin Invest 1998; 101: 1184-94.
37. Lou XJ, Boonmark NW, Horrigan FT, Degen JL, Lawn RM. Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice. Proc Natl Acad Sci USA 1998; 95: 12591-5.
38. Iwaki T, Sandoval-Cooper MJ, Brechmann M, Ploplis VA, Castellino FJ. A fibrinogen deficiency accelerates the initiation of LDL cholesterol-driven atherosclerosis via thrombin generation and platelet activation in genetically predisposed mice. Blood 2006; 107: 3883-91.
39. Voetsch B, Loscalzo J. Genetics of thrombophilia: impact on atherogenesis. Curr Opin Lipidol 2004; 15: 129-43.
40. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 2003; 146: 948-57.
41. Ye Z, Liu EHC, Higgins JPT, Keavney BD, Lowe GDO, Collins R, Danesh J. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66, 155 cases and 91, 307 controls. Lancet 2006; 367: 651-8.
42. Weischer M, Juul K, Zacho J, Jensen GB, Steffensen R, Schroeder TV, Tybjaerg-Hansen A, Nordestgaard BG. Prothrombin and risk of venous thromboembolism, ischemic heart disease and ischemic cerebrovascular disease in the general population. Atherosclerosis 2010; 208: 480-3.
43. Martinelli N, Trabetti E, Pinotti M, Olivieri O, Sandri M, Friso S, Pizzolo F, Bozzini C, Caruso PP, Cavallari U, Cheng S, Pignatti PF, Bernardi F, Corrocher R, Girelli D. Combined effect of hemostatic gene polymorphisms and the risk of myocardial infarction in patients with advanced coronary atherosclerosis. PLoS ONE 2008; 3: e1523.
44. de Moerloose P, Boehlen F. Inherited thrombophilia in arterial disease: a selective review. Semin Hematol 2007; 44: 106-13.
45. Burzotta F, Paciaroni K, De Stefano V, Crea F, Maseri A, Leone G, Andreotti F. G20210A prothrombin gene polymorphism and coronary ischaemic syndromes: a phenotype-specific meta-analysis of 12034 subjects. Heart 2004; 90: 82-6.
46. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210G to A) increases the risk of myocardial infarction in young women. Blood 1997; 90: 1747-50.
47. Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT, Raghunathan TE, Koepsell TD, Reitsma PH. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89: 2817-21.
48. Dacosta A, Tardy-Poncet B, Isaaz K, Cerisier A, Mismetti P, Simitsidis S, Reynaud J, Tardy B, Piot M, Decousus H, Guyotat D. Prevalence of factor V Leiden (APCR) and other inherited thrombophilias in young patients with myocardial infarction and normal coronary arteries. Heart 1998; 80: 338-40.
49. Mahmoodi BK, Brouwer J-LP, Veeger NJGM, van der Meer J. Hereditary deficiency of protein C or protein S confers increased risk of arterial thromboembolic events at a young age: results from a large family cohort study. Circulation 2008; 118: 1659-67.
50. Marcucci R, Sofi F, Fedi S, Lari B, Sestini I, Cellai AP, Pulli R, Pratesi G, Pratesi C, Gensini GF, Abbate R. Thrombophilic risk factors in patients with severe carotid atherosclerosis. J Thromb Haemost 2005; 3: 502-7.
51. Casas JP, Hingorani AD, Bautista LE, Sharma P. Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18, 000 cases and 58, 000 controls. Arch Neurol 2004; 61: 1652-61.
52. Juul K, Tybjaerg-Hansen A, Steffensen R, Kofoed S, Jensen G, Nordestgaard BG. Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses. Blood 2002; 100: 3-10.
53. Middendorf K, Göhring P, Huehns TY, Seidel D, Steinbeck G, Nikol S. Prevalence of resistance against activated protein C resulting from factor V Leiden is significantly increased in myocardial infarction: investigation of 507 patients with myocardial infarction. Am Heart J 2004; 147: 897-904.
54. Sartori M, Favaretto E, Legnani C, Cini M, Conti E, Amato A, Palareti G. Thrombophilic risk factors and peripheral arterial disease severity. Thromb Haemost 2010; 104: 71-7.
55. Sofi F, Lari B, Rogolino A, Marcucci R, Pratesi G, Dorigo W, Pratesi C, Gensini GF, Abbate R, Prisco D. Thrombophilic risk factors for symptomatic peripheral arterial disease. J Vasc Surg 2005; 41: 255-60.
56. Houbballah R, LaMuraglia GM. Clotting problems: diagnosis and management of underlying coagulopathies. Semin Vasc Surg 2010; 23: 221-7.
57. Santos RD, Nasir K. Insights into atherosclerosis from invasive and non-invasive imaging studies: should we treat subclinical atherosclerosis? Atherosclerosis 2009; 205: 349-56.
58. Griggs RM, Bluth EI. Noninvasive risk assessment for stroke: special emphasis on carotid atherosclerosis, sex-related differences, and the development of an effective screening strategy. AJR Am J Roentgenol 2011; 196: 259-64.
59. de Groot E, Hovingh GK, Wiegman A, Duriez P, Smit AJ, Fruchart J-C, Kastelein JJP. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation 2004; 109: III33-8.
60. Baldassarre D, Amato M, Bondioli A, Sirtori CR, Tremoli E. Carotid artery intima-media thickness measured by ultrasonography in normal clinical practice correlates well with atherosclerosis risk factors. Stroke 2000; 31: 2426-30.
61. Ibañez B, Badimon JJ, Garcia MJ. Diagnosis of atherosclerosis by imaging. Am J Med 2009; 122: S15-25.
62. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997; 96: 1432-7.
63. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14-22.
64. Wintermark M, Jawadi SS, Rapp JH, Tihan T, Tong E, Glidden DV, Abedin S, Schaeffer S, Acevedo-Bolton G, Boudignon B, Orwoll B, Pan X, Saloner D. High-resolution CT imaging of carotid artery atherosclerotic plaques. AJNR Am J Neuroradiol 2008; 29: 875-82.
65. Corti R, Binggeli C, Turina M, Jenni R, Lüscher TF, Turina J. Predictors of long-term survival after valve replacement for chronic aortic regurgitation; is M-mode echocardiography sufficient? Eur Heart J 2001; 22: 866-73.
66. Fox CS, Larson MG, Corey D, Feng D, Lindpaintner K, Polak JF, Wolf PA, D'Agostino RB, Tofler GH, O'Donnell CJ. Absence of association between polymorphisms in the hemostatic factor pathway genes and carotid intimal medial thickness: the Framingham Heart Study. Stroke 2004; 35: e65-7.
67. Palareti G, Valdré L, Favaretto E, Bovina V, Cini M, Legnani C. No early signs of atherosclerotic alterations in carriers of inherited thrombophilia. Eur J Intern Med 2010; 21: 273-7.
68. Darby SC, Kan SW, Spooner RJ, Giangrande PLF, Hill FGH, Hay CRM, Lee CA, Ludlam CA, Williams M. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007; 110: 815-25.
69. Plug I, van der Bom JG, Peters M, Mauser-Bunschoten EP, De Goede-Bolder A, Heijnen L, Smit C, Willemse J, Rosendaal FR. Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study. J Thromb Haemost 2006; 4: 510-16.
70. Triemstra M, Rosendaal FR, Smit C, van der Ploeg HM, Briët E. Mortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986. Ann Intern Med 1995; 123: 823-7.
71. Ragni MV. Aging in haemophilia: getting to the heart of the matter. Thromb Haemost 2011; 105: 207-8.
72. Srámek A, Kriek M, Rosendaal FR. Decreased mortality of ischaemic heart disease among carriers of haemophilia. Lancet 2003; 362: 351-4.
73. Biere-Rafi S, Zwiers M, Peters M, van der Meer J, Rosendaal FR, Buller HR, Kamphuisen PW. The effect of haemophilia and von Willebrand disease on arterial thrombosis: a systematic review. Neth J Med 2010; 68: 207-14.
74. Biere-Rafi S, Tuinenburg A, Haak BW, Peters M, Huijgen R, de Groot E, Verhamme P, Peerlick K, Visseren FL, Kruip MJ, Laros-Van Gorkom BA, Gerdes VE, Buller HR, Schutgens RE, Kamphuisen PW. Factor VIII deficiency does not protect against atherosclerosis. J Thromb Haemost 2012; 10: 30-7.
75. Foley CJ, Nichols L, Jeong K, Moore CG, Ragni MV. Coronary atherosclerosis and cardiovascular mortality in hemophilia. J Thromb Haemost 2010; 8: 208-11.
76. Tuinenburg A, Rutten A, Kavousi M, Leebeek FW, Ypma PF, Laros-van Gorkom BA, Nijziel MR, Kamphuisen PW, Mauser-Bunschoten EP, Roosendaal G, Biesma DH, van der Lugt A, Hofman A, Witteman JC, Bots ML, Schutgens RE. Coronary Artery Calcification in Hemophilia A: No Evidence for a Protective Effect of Factor VIII Deficiency on Atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32: 799-804.
77. Zwiers M, Lefrandt JD, Mulder DJ, Smit AJ, Gans RO, Vliegenthart R, Brands-Nijenhuis AV, Kluin-Nelemans JC, Meijer K. Coronary Artery Calcification Score and Carotid Intima Media Thickness in Patients With Haemophilia. J Thromb Haemost 2012; 10: 23-9.
78. Bilora F, Zanon E, Petrobelli F, Cavraro M, Prandoni P, Pagnan A, Girolami A. Does hemophilia protect against atherosclerosis? A case-control study Clin Appl Thromb Hemost 2006; 12: 193-8.
79. Srámek A Sr, Reiber JH, Gerrits WB, Rosendaal FR. Decreased coagulability has no clinically relevant effect on atherogenesis: observations in individuals with a hereditary bleeding tendency. Circulation 2001; 104: 762-7.
80. Biere SSAY, van Weyenberg SJB, Verheul HMW, Mulder CJJ, Cuesta MA, van der Peet DL. Non-metastasized oesophageal cancer. Ned Tijdschr Geneeskd 2010; 154: A820.
81. Dielis AWJH, Castoldi E, Spronk HMH, van Oerle R, Hamulyák K, ten Cate H, Rosing J. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost 2008; 6: 125-31.
82. Spronk HM, van der Voort D, ten Cate H. Blood coagulation and the risk of atherothrombosis: a complex relationship. Thromb J 2004; 2: 2-12.
83. Cortellaro M, Cofrancesco E, Boschetti C, Mussoni L, Donati MB, Catalano M, Gabrielli L, Lombardi B, Specchia G, Tavazzi L. Association of increased fibrin turnover and defective fibrinolytic capacity with leg atherosclerosis. The PLAT Group. Thromb Haemost 1994; 72: 292-6.
84. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Rumley A, Lowe GD. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation 2001; 103: 2323-7.
85. Komarov A, Panchenko E, Dobrovolsky A, Karpov Y, Deev A, Titaeva E, Davletov K, Eshkeeva A, Markova L. D-dimer and platelet aggregability are related to thrombotic events in patients with peripheral arterial occlusive disease. Eur Heart J 2002; 23: 1309-16.
86. Lassila R, Peltonen S, Lepäntalo M, Saarinen O, Kauhanen P, Manninen V. Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin. Arterioscler Thromb 1993; 13: 1738-42.
87. Lowe G. Can haemostatic factors predict atherothrombosis? Intern Emerg Med 2011; 6: 497-501.
88. Scott EM, Ariëns RAS, Grant PJ. Genetic and environmental determinants of fibrin structure and function: relevance to clinical disease. Arterioscler Thromb Vasc Biol 2004; 24: 1558-66.
89. Lowe GDO, Sweetnam PM, Yarnell JWG, Rumley A, Rumley C, Bainton D, Ben-Shlomo Y. C-reactive protein, fibrin D-dimer, and risk of ischemic heart disease: the Caerphilly and Speedwell studies. Arterioscler Thromb Vasc Biol 2004; 24: 1957-62.
90. Narins CR, Zareba W, Moss AJ, Marder VJ, Ridker PM, Krone RJ, Lichstein E. Relationship between intermittent claudication, inflammation, thrombosis, and recurrent cardiac events among survivors of myocardial infarction. Arch Intern Med 2004; 164: 440-6.
91. Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK. Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities Study. Circulation 1995; 91: 284-90.
92. Smith FB, Rumley A, Lee AJ, Leng GC, Fowkes FG, Lowe GD. Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants. Br J Haematol 1998; 100: 758-63.
93. Tataru MC, Heinrich J, Junker R, Schulte H, von Eckardstein A, Assmann G, Koehler E. D-dimers in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction. Eur Heart J 1999; 20: 1493-502.
94. van der Bom JG, Bots ML, Haverkate F, Meijer P, Hofman A, Kluft C, Grobbee DE. Activation products of the haemostatic system in coronary, cerebrovascular and peripheral arterial disease. Thromb Haemost 2001; 85: 234-9.
95. Folsom AR, Aleksic N, Park E, Salomaa V, Juneja H, Wu KK. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 2001; 21: 611-17.
96. Páramo JA, Orbe J, Beloqui O, Benito A, Colina I, Martinez-Vila E, Diez J. Prothrombin fragment1+2 is associated with carotid intima-media thickness in subjects free of clinical cardiovascular disease. Stroke 2004; 35: 1085-9.
97. Kienast J, Thompson SG, Raskino C, Pelzer H, Fechtrup C, Ostermann H, van de Loo J. Prothrombin activation fragment 1+2 and thrombin antithrombin III complexes in patients with angina pectoris: relation to the presence and severity of coronary atherosclerosis. Thromb Haemost 1993; 70: 550-3.
98. Henareh L, Jogestrand T, Agewall S. Prothrombin fragment 1+2 is associated with intima media thickness of the carotid artery in patients with myocardial infarction. Thromb Res 2009; 124: 526-30.
99. Di Tullio MR, Homma S, Jin Z, Sacco RL. Aortic atherosclerosis, hypercoagulability, and stroke: the APRIS (Aortic Plaque and Risk of Ischemic Stroke) study. J Am Coll Cardiol 2008; 52: 855-61.
100. Borissoff JI, Joosen IA, Versteylen MO, Spronk HMH, ten Cate H, Hofstra L. Accelerated in vivo thrombin formation independently predicts the presence and severity of CT-angiographic coronary atherosclerosis. J Am Coll Cardiol Img 2012; (in press).
101. Smid M, Dielis AWJH, Winkens M, Spronk HMH, van Oerle R, Hamulyák K, Prins MH, Rosing J, Waltenberger JL, ten Cate H. Thrombin generation in patients with a first acute myocardial infarction. J Thromb Haemost 2011; 9: 450-6.
102. Winckers K, Siegerink B, Duckers C, Maurissen LF, Tans G, Castoldi E, Spronk HMH, ten Cate H, Algra A, Hackeng TM, Rosendaal FR. Increased tissue factor pathway inhibitor activity is associated with myocardial infarction in young women: results from the RATIO study. J Thromb Haemost 2011; 9: 2243-50.
103. Minnema MC, Peters RJ, de Winter R, Lubbers YP, Barzegar S, Bauer KA, Rosenberg RD, Hack CE, ten Cate H. Activation of clotting factors XI and IX in patients with acute myocardial infarction. Arterioscler Thromb Vasc Biol 2000; 20: 2489-93.
104. Undas A, Szuldrzyński K, Brummel-Ziedins KE, Tracz W, Zmudka K, Mann KG. Systemic blood coagulation activation in acute coronary syndromes. Blood 2009; 113: 2070-8.
105. Undas A, Slowik A, Gissel M, Mann KG, Butenas S. Circulating activated factor XI and active tissue factor as predictors of worse prognosis in patients following ischemic cerebrovascular events. Thromb Res 2011; 128: e62-6.
106. ten Cate H, Bauer KA, Levi M, Edgington TS, Sublett RD, Barzegar S, Kass BL, Rosenberg RD. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 1993; 92: 1207-12.
107. Breitenstein A, Tanner FC, Lüscher TF. Tissue factor and cardiovascular disease: quo vadis? Circ J 2010; 74: 3-12.
108. van der Meijden PEJ, van Schilfgaarde M, van Oerle R, Renné T, ten Cate H, Spronk HMH. Platelet- and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa. J Thromb Haemost 2012; 10: 1355-62.
109. Matafonov A, Sarilla S, Sun M-F, Sheehan JP, Serebrov V, Verhamme IM, Gailani D. Activation of factor XI by products of prothrombin activation. Blood 2011; 118: 437-45.
110. Govers-Riemslag JWP, Smid M, Cooper JA, Bauer KA, Rosenberg RD, Hack CE, Hamulyák K, Spronk HMH, Miller GJ, ten Cate H. The plasma kallikrein-kinin system and risk of cardiovascular disease in men. J Thromb Haemost 2007; 5: 1896-903.
111. Siegerink B, Govers-Riemslag JWP, Rosendaal FR, ten Cate H, Algra A. Intrinsic coagulation activation and the risk of arterial thrombosis in young women: results from the Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) case-control study. Circulation 2010; 122: 1854-61.
112. Kleinschnitz C, Stoll G, Bendszus M, Schuh K, Pauer H-U, Burfeind P, Renné C, Gailani D, Nieswandt B, Renné T. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006; 203: 513-18.
113. Blum A, Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 2009; 203: 325-30.
114. Hirano K. The roles of proteinase-activated receptors in the vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 2007; 27: 27-36.
115. Andersen H, Greenberg DL, Fujikawa K, Xu W, Chung DW, Davie EW. Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Natl Acad Sci USA 1999; 96: 11189-93.
116. Chintala M, Strony J, Yang B, Kurowski S, Li Q. SCH 602539, a protease-activated receptor-1 antagonist, inhibits thrombosis alone and in combination with cangrelor in a Folts model of arterial thrombosis in cynomolgus monkeys. Arterioscler Thromb Vasc Biol 2010; 30: 2143-9.
117. Takada M, Tanaka H, Yamada T, Ito O, Kogushi M, Yanagimachi M, Kawamura T, Musha T, Yoshida F, Ito M, Kobayashi H, Yoshitake S, Saito I. Antibody to thrombin receptor inhibits neointimal smooth muscle cell accumulation without causing inhibition of platelet aggregation or altering hemostatic parameters after angioplasty in rat. Circ Res 1998; 82: 980-7.
118. Cheung WM, D'Andrea MR, Andrade-Gordon P, Damiano BP. Altered vascular injury responses in mice deficient in protease-activated receptor-1. Arterioscler Thromb Vasc Biol 1999; 19: 3014-24.
119. Andrade-Gordon P, Derian CK, Maryanoff BE, Zhang HC, Addo MF, Cheung WM, Damiano BP, D'Andrea MR, Darrow AL, de Garavilla L, Eckardt AJ, Giardino EC, Haertlein BJ, McComsey DF. Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats. J Pharmacol Exp Ther 2001; 298: 34-42.
120. Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LHK, Ambrosio G, Bode C, Cequier A, Cornel JH, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012; 366: 20-33.
121. Spronk HMH. Vitamin K epoxide reductase complex and vascular calcification: is this the important link between vitamin K and the arterial vessel wall? Circulation 2006; 113: 1550-2.
122. Spronk HMH, Soute BAM, Schurgers LJ, Thijssen HHW, de Mey JGR, Vermeer C. Tissue-specific utilization of menaquinone-4 results in the prevention of arterial calcification in warfarin-treated rats. J Vasc Res 2003; 40: 531-7.
123. Price PA, Faus SA, Williamson MK. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998; 18: 1400-7.
124. Rennenberg RJMW, van Varik BJ, Schurgers LJ, Hamulyák K, ten Cate H, Leiner T, Vermeer C, de Leeuw PW, Kroon AA. Chronic coumarin treatment is associated with increased extracoronary arterial calcification in humans. Blood 2010; 115: 5121-3.
125. Weijs B, Blaauw Y, Rennenberg RJMW, Schurgers LJ, Timmermans CCMM, Pison L, Nieuwlaat R, Hofstra L, Kroon AA, Wildberger J, Crijns HJGM. Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients. Eur Heart J 2011; 32: 2555-62.
126. Breyne J, Juthier F, Corseaux D, Marechaux S, Zawadzki C, Jeanpierre E, Ung A, Ennezat PV, Susen S, van Belle E, Le Marec H, Vincentelli A, Le Tourneau T, Jude B. Atherosclerotic-like process in aortic stenosis: activation of the tissue factor-thrombin pathway and potential role through osteopontin alteration. Atherosclerosis 2010; 213: 369-76.
127. Roach HI. Why does bone matrix contain non-collagenous proteins? The possible roles of osteocalcin, osteonectin, osteopontin and bone sialoprotein in bone mineralisation and resorption. Cell Biol Int 1994; 18: 617-28.
128. Scatena M, Liaw L, Giachelli CM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 2007; 27: 2302-9.
129. Bea F, Kreuzer J, Preusch M, Schaab S, Isermann B, Rosenfeld ME, Katus H, Blessing E. Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2006; 26: 2787-92.
130. Zhou Q, Bea F, Preusch M, Wang H, Isermann B, Shahzad K, Katus HA, Blessing E. Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. Mediators Inflamm 2011; doi:10.1155/2011/432080.
131. Mega JL, Braunwald E, Wiviott SD, Bassand J-P, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KAA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FWA, Gibson CM; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19.
132. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; 172: 397-402.